Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Hanbyeol Kim, Jeongbae Park, Jeong‐Mok Kim
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2100-2100
Open Access | Times Cited: 15

Showing 15 citing articles:

Emerging prodrug and nano-drug delivery strategies for the detection and elimination of senescent tumor cells
Tao Wang, Xianbao Shi, Xiaolong Xu, et al.
Biomaterials (2025), pp. 123129-123129
Closed Access | Times Cited: 2
PROTACs: Novel tools for improving immunotherapy in cancer
Shizhe Li, Ting Chen, Jinxin Liu, et al.
Cancer Letters (2023) Vol. 560, pp. 216128-216128
Closed Access | Times Cited: 25
Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development
Mohd Danishuddin, Mohammad Sarwar Jamal, Kyoung Seob Song, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 12, pp. 1649-1649
Open Access | Times Cited: 17
Emerging paradigms and recent progress in targeting ErbB in cancers
Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 552-576
Open Access | Times Cited: 5
Preclinical Anticipation of On- and Off-Target Resistance Mechanisms to Anti-Cancer Drugs: A Systematic Review
Paulina J. Dziubańska-Kusibab, Ekaterina Nevedomskaya, Bernard Haendler
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 705-705
Open Access | Times Cited: 4
Exploring the clinical trials, regulatory insights, and challenges of PROTACs in oncology
M Sowndharya, Ramesh Joga, Kajal Gandhi, et al.
Seminars in Oncology (2025) Vol. 52, Iss. 2, pp. 152339-152339
Closed Access
Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies
Aleksandra Mordzińska-Rak, Ilona Telejko, Grzegorz Adamczuk, et al.
Biomedicines (2025) Vol. 13, Iss. 5, pp. 1046-1046
Open Access
Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)
Amr E. Abbas, Fei Ye
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134293-134293
Closed Access | Times Cited: 3
CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications
Riya Thapa, Asif Ahmad Bhat, Gaurav Gupta, et al.
Chemical Biology & Drug Design (2024) Vol. 104, Iss. 5
Open Access | Times Cited: 3
The rise of targeting chimeras (TACs): next-generation medicines that preempt cellular events
Scott A. Hollingsworth, S.A. Johnson, Pouyan Khakbaz, et al.
Medicinal Chemistry Research (2023) Vol. 32, Iss. 7, pp. 1294-1314
Closed Access | Times Cited: 3
Structural study for substrate recognition of human N‐terminal glutamine amidohydrolase 1 in the arginine N‐degron pathway
Jin Kang, Joon Sung Park, Jae Seok Lee, et al.
Protein Science (2024) Vol. 33, Iss. 7
Open Access
Advantages and Disadvantages of PROTACs
Rohini Pujari, Shvetank Bhatt, Urvashi Soni, et al.
(2024), pp. 67-88
Closed Access
Next-Generation Cancer Therapeutics: PROTACs and the Role of Heterocyclic Warheads in Targeting Resistance
Effat Omar, Rajendiran Rajesh, Pronoy Kanti Das, et al.
European Journal of Medicinal Chemistry (2024) Vol. 281, pp. 117034-117034
Closed Access
Targeting mammalian N-end rule pathway for cancer therapy
Shria Mattoo, Mansi Arora, Priyanka Sharma, et al.
Biochemical Pharmacology (2024), pp. 116684-116684
Closed Access
Protacs in cancer therapy: mechanisms, design, clinical trials, and future directions
Akash Vikal, Rashmi Maurya, Brij Bihari Patel, et al.
Drug Delivery and Translational Research (2024)
Closed Access
Revolutionizing lung cancer treatment: Introducing PROTAC therapy as a novel paradigm in targeted therapeutics
Atharva Anand Mahajan, Gauri Panzade, Tiyasa Bhuniya, et al.
Current Problems in Cancer (2024) Vol. 54, pp. 101172-101172
Closed Access
Special Issue: Resistance to Targeted Therapies in Human Cancer
Tae‐Won Lee, Hee‐Joo Choi, Kyung‐min Lee, et al.
Biomedicines (2023) Vol. 11, Iss. 2, pp. 414-414
Open Access
Page 1

Scroll to top